| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/31/2003 | CA2473781A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | CA2473721A1 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia |
| 07/31/2003 | CA2473545A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2473536A1 Pharmaceutical composition and method for treating disorders of the central nervous system |
| 07/31/2003 | CA2473510A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 07/31/2003 | CA2473508A1 Pyrimidinone viral polymerase inhibitors |
| 07/31/2003 | CA2473490A1 Peptide-carrying bodies for immune response |
| 07/31/2003 | CA2473474A1 Alteration of rab38 function to modulate mammalian pigmentation |
| 07/31/2003 | CA2473420A1 Tricyclic 2-pyrimidone compounds useful as hiv reverse transcriptase inhibitors |
| 07/31/2003 | CA2473395A1 Phospholipid bodies and use thereof in medical treatment |
| 07/31/2003 | CA2473254A1 Combination therapy for the treatment of bacterial infections |
| 07/31/2003 | CA2473047A1 Phosphinic pseudo-peptide derivatives for selective inhibition of the active c-terminal site of angiotensin converting enzyme (i) (ace) |
| 07/31/2003 | CA2473036A1 Melanocortin receptor agonists |
| 07/31/2003 | CA2473032A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 07/31/2003 | CA2472835A1 Fused bicyclic pyrimidine derivatives |
| 07/31/2003 | CA2472682A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | CA2472578A1 Anti-cancer combination and use thereof |
| 07/31/2003 | CA2472367A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | CA2472241A1 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
| 07/31/2003 | CA2472239A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | CA2472238A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | CA2472186A1 Combination il-2/anti-her2 antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
| 07/31/2003 | CA2471989A1 2-aminothiazole allosteric enhancers of a1 adenosine receptors |
| 07/31/2003 | CA2471740A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | CA2471639A1 Novel alkyl/aryl hydroxy or keto thiepines. |
| 07/30/2003 | EP1331269A1 Novel protein, process for producing the same and use thereof |
| 07/30/2003 | EP1331268A1 Novel proteins, genes encoding them and method of using the same |
| 07/30/2003 | EP1331224A1 Thiazole or oxazole derivatives |
| 07/30/2003 | EP1331223A1 Method of treating sepsis |
| 07/30/2003 | EP1330999A1 Melanogenesis inhibitors and whitening agents comprising ergosterol derivative and compositions containing ergosterol derivative |
| 07/30/2003 | EP1330548A2 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries |
| 07/30/2003 | EP1330537A1 Membrane fractions of 1,2-sn-diacylglycerol-enriched cells |
| 07/30/2003 | EP1330535A2 Kini-3 motor protein and methods for its use |
| 07/30/2003 | EP1330528A2 Regulation of human serine-threonine protein kinase |
| 07/30/2003 | EP1330522A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 07/30/2003 | EP1330521A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 07/30/2003 | EP1330520A2 Therapeutic oligonucleotides of reduced toxicity |
| 07/30/2003 | EP1330470A1 Glutathione conjugates with distamycin derivatives having antitumor activity |
| 07/30/2003 | EP1330467A2 Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
| 07/30/2003 | EP1330463A2 Beta-substituted beta-aminoethyl phosphonates |
| 07/30/2003 | EP1330459A2 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 07/30/2003 | EP1330455A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 07/30/2003 | EP1330453A1 Indolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 07/30/2003 | EP1330452A2 Pyrazine derivatives as modulators of tyrosine kinases |
| 07/30/2003 | EP1330451A2 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators |
| 07/30/2003 | EP1330448A2 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 07/30/2003 | EP1330444A2 Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof |
| 07/30/2003 | EP1330442A1 Phthalazinone derivatives |
| 07/30/2003 | EP1330439A1 (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine |
| 07/30/2003 | EP1330435A1 Crystalline forms of fluvastatin sodium |
| 07/30/2003 | EP1330432A2 Substituted alkanoic acids |
| 07/30/2003 | EP1330430A2 Integrin receptor inhibitors |
| 07/30/2003 | EP1330427A1 Crystalline forms of venlafaxine hydrochloride |
| 07/30/2003 | EP1330426A1 Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 07/30/2003 | EP1330293A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 07/30/2003 | EP1330268A1 Targeted therapeutic agents |
| 07/30/2003 | EP1330267A1 Olfactory neuron cultures and method of making and using the same |
| 07/30/2003 | EP1330253A1 Use of bioactive fraction from cow urine distillate ('go mutra') as a bio-enhancer of anti-infective, anti-cancer agents and nutrients |
| 07/30/2003 | EP1330252A1 In vivo stimulation of angiogenic activity |
| 07/30/2003 | EP1330251A1 Combination therapy for the treatment of estrogen-sensitive disease |
| 07/30/2003 | EP1330245A1 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| 07/30/2003 | EP1330243A2 Use of carp inhibitors for the treatment of heart diseases |
| 07/30/2003 | EP1330240A2 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 07/30/2003 | EP1330238A1 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| 07/30/2003 | EP1330237A2 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 07/30/2003 | EP1330166A1 Food grade transglutaminase inhibitor and uses thereof |
| 07/30/2003 | EP1252141B1 Tosylproline analogs as thymidylate synthase inhibitors |
| 07/30/2003 | EP1233960B1 Polymorphic salt of an anti-migraine drug |
| 07/30/2003 | EP1187817B1 Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same |
| 07/30/2003 | EP1184388B1 Sulphostin analogues and processes for the preparation of sulphostin and analogues thereof |
| 07/30/2003 | EP1180035A4 NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1$g(a), 25-DIHYDROXY VITAMIN D 3? |
| 07/30/2003 | EP1178832B1 Novel medicament compositions, based on tiotropium bromide and salmeterol |
| 07/30/2003 | EP1171100B1 Solubilized pharmaceutical composition for parenteral administration |
| 07/30/2003 | EP1157037B1 Gcsf conjugates |
| 07/30/2003 | EP1112275B1 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| 07/30/2003 | EP1082962B1 Utilization of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factors nf-(k)b |
| 07/30/2003 | EP1075256B1 Arylhydrocarbon receptor ligand antagonists |
| 07/30/2003 | EP1052989B1 Use of 2-amino-6- trifluoromehthoxy- benzothiazole for preventing or treating cerebellum dysfunction |
| 07/30/2003 | EP0966286B1 Attenuation of opioid tolerance by inhibiting inducible nitric oxide synthase pathways in the treatment of pain |
| 07/30/2003 | EP0946541B1 Quinolines and their therapeutic use |
| 07/30/2003 | EP0902022B1 Novel benzofuranone derivatives and process for producing the same |
| 07/30/2003 | EP0832198B1 Oxygen activatable formulations for disinfection or sterilization |
| 07/30/2003 | EP0831884B1 Use of bone morphogenic proteins for healing and repair of connective tissue attachment |
| 07/30/2003 | EP0814801B1 Use of a pyruvate dehydrogenase activator for the treatment of ischaemia in limbs |
| 07/30/2003 | EP0785793B1 Allosteric modulators of the nmda receptor |
| 07/30/2003 | EP0705100B1 Therapeutic substituted guanidines |
| 07/30/2003 | EP0592439B1 Aminosulfonyl carbamates |
| 07/30/2003 | CN1433478A Novel colloid synthetic vectors for gene therapy |
| 07/30/2003 | CN1433477A Method of achieving persistent transgene expression |
| 07/30/2003 | CN1433469A Therapeutically useful synthetic oligonucleotides |
| 07/30/2003 | CN1433466A MASP-3, complement-fixing enzyme, and uses for it |
| 07/30/2003 | CN1433427A 依匹乐酮晶型 Epinastine music one polymorph |
| 07/30/2003 | CN1433424A 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 07/30/2003 | CN1433417A Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| 07/30/2003 | CN1433416A N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamideinhibitors of cyclin dependent kinases |
| 07/30/2003 | CN1433415A N-[5-[[[5-alkyl-2-oxazlyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
| 07/30/2003 | CN1433411A Chemical compounds |
| 07/30/2003 | CN1433410A CDK inhibitors having 3-hydroxychromen-4-one structure |
| 07/30/2003 | CN1433408A Aminothiazole inhibitors of cyslin dependent kinases |
| 07/30/2003 | CN1433407A Bis-arylsulfones |